Literature DB >> 23487468

Directed evolution of mutator adenoviruses resistant to antibody neutralization.

Nicolle D Myers1, Ksenia V Skorohodova, Anshu P Gounder, Jason G Smith.   

Abstract

We incorporated a previously identified mutation that reduces the fidelity of the DNA polymerase into a human adenovirus vector. Using this mutator vector, we demonstrate rapid selection of resistance to a neutralizing anti-hexon monoclonal antibody due to a G434D mutation in hexon that precludes antibody binding. Since mutator adenoviruses can accumulate compound mutations that are unattainable using traditional random mutagenesis techniques, this approach will be valuable to the study of antivirals and host factor interactions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23487468      PMCID: PMC3648140          DOI: 10.1128/JVI.00473-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  Antipeptide antisera define neutralizing epitopes on the adenovirus hexon.

Authors:  C I Toogood; J Crompton; R T Hay
Journal:  J Gen Virol       Date:  1992-06       Impact factor: 3.891

2.  Regulation of virus neutralization and the persistent fraction by TRIM21.

Authors:  W A McEwan; F Hauler; C R Williams; S R Bidgood; D L Mallery; R A Crowther; L C James
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

Review 3.  Rates of spontaneous mutation.

Authors:  J W Drake; B Charlesworth; D Charlesworth; J F Crow
Journal:  Genetics       Date:  1998-04       Impact factor: 4.562

4.  Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization.

Authors:  P L Stewart; C Y Chiu; S Huang; T Muir; Y Zhao; B Chait; P Mathias; G R Nemerow
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

5.  An antigenic analysis of the adenovirus type 2 fibre polypeptide.

Authors:  G Watson; M G Burdon; W C Russell
Journal:  J Gen Virol       Date:  1988-03       Impact factor: 3.891

6.  Postentry neutralization of adenovirus type 5 by an antihexon antibody.

Authors:  Robin Varghese; Yeshi Mikyas; Phoebe L Stewart; Robert Ralston
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

7.  Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir.

Authors:  Y J Gordon; T P Araullo-Cruz; Y F Johnson; E G Romanowski; P R Kinchington
Journal:  Invest Ophthalmol Vis Sci       Date:  1996-12       Impact factor: 4.799

8.  Immunoreactive domains and integrin-binding motifs in adenovirus penton base capsomer.

Authors:  S S Hong; M Bardy; M Monteil; B Gay; C Denesvre; J Tournier; G Martin; M Eloit; P Boulanger
Journal:  Viral Immunol       Date:  2000       Impact factor: 2.257

9.  Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors.

Authors:  Saw See Hong; Nagy A Habib; Laure Franqueville; Steen Jensen; Pierre A Boulanger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes.

Authors:  J Gall; A Kass-Eisler; L Leinwand; E Falck-Pedersen
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more
  5 in total

1.  An Adaptable Platform for Directed Evolution in Human Cells.

Authors:  Chet M Berman; Louis J Papa; Samuel J Hendel; Christopher L Moore; Patreece H Suen; Alexander F Weickhardt; Ngoc-Duc Doan; Caiden M Kumar; Taco G Uil; Vincent L Butty; Robert C Hoeben; Matthew D Shoulders
Journal:  J Am Chem Soc       Date:  2018-12-14       Impact factor: 15.419

2.  Identification and Application of Neutralizing Epitopes of Human Adenovirus Type 55 Hexon Protein.

Authors:  Xingui Tian; Qiang Ma; Zaixue Jiang; Junfeng Huang; Qian Liu; Xiaomei Lu; Qingming Luo; Rong Zhou
Journal:  Viruses       Date:  2015-10-27       Impact factor: 5.048

3.  Small-size recombinant adenoviral hexon protein fragments for the production of virus-type specific antibodies.

Authors:  Martin Pacesa; Rodinde Hendrickx; Manuela Bieri; Justin W Flatt; Urs F Greber; Silvio Hemmi
Journal:  Virol J       Date:  2017-08-18       Impact factor: 4.099

4.  Defensin-driven viral evolution.

Authors:  Karina Diaz; Ciara T Hu; Youngmee Sul; Beth A Bromme; Nicolle D Myers; Ksenia V Skorohodova; Anshu P Gounder; Jason G Smith
Journal:  PLoS Pathog       Date:  2020-11-24       Impact factor: 6.823

5.  Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control.

Authors:  Markus Schmid; Patrick Ernst; Annemarie Honegger; Maarit Suomalainen; Martina Zimmermann; Lukas Braun; Sarah Stauffer; Cristian Thom; Birgit Dreier; Matthias Eibauer; Anja Kipar; Viola Vogel; Urs F Greber; Ohad Medalia; Andreas Plückthun
Journal:  Nat Commun       Date:  2018-01-31       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.